1377582-59-6

Basic information

• Product Name: 3-Isothiocyanato-4-trifluoromethoxy-benzenesulfonamide
• Synonyms: 3-Isothiocyanato-4-trifluoromethoxy-benzenesulfonamide
• CAS NO: 1377582-59-6
• Molecular Weight: 298.267
• Mol File: 1377582-59-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-Isothiocyanato-4-trifluoromethoxy-benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Isothiocyanato-4-trifluoromethoxy-benzenesulfonamide(1377582-59-6)
• EPA Substance Registry System: 3-Isothiocyanato-4-trifluoromethoxy-benzenesulfonamide(1377582-59-6)

Safety Data

• Hazardous Substances Data: 1377582-59-6(Hazardous Substances Data)

Upstream product

• 1644-88-8 o-nitro-α,α,α-trifluoromethoxybenzene 
• 1377582-58-5 3-Nitro-4-trifluoromethoxy-benzenesulfonamide 
• 463-71-8 thiophosgene 
• 1261523-68-5 3-Amino-4-trifluoromethoxy-benzenesulfonamide 

Downstream Products

• 1377582-60-9 3-thioureido-(4-trifluoromethoxy)benzenesulfonamide 
• 1377961-34-6 3-(4-Pyridin-3-yl-thiazol-2-ylamino)-4-trifluoromethoxy-benzenesulfonamide 
• 1377583-46-4 3-(2',4'-dimethyl-[4,5']bithiazolyl-2-ylamino)-4-trifluoromethoxy-benzenesulfonamide 

Relevant articles and documents

PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to phenyl thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.